Ophthalmic Partners PC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$111,134	11
2024	Research	$47,481	13
2023	Research	$87,521	16
2022	Research	$54,823	5
2021	Research	$34,727	10

Breakdown

Who paid Research payments · program years 2021–2025

AbbVie, Inc. $184,148 26 payments
Sight Sciences, Inc. $77,295 6 payments
Glaukos Corporation $39,515 13 payments
Kowa Research Institute, Inc. $34,727 10 payments

Studies the money was for Research payments · program years 2021–2025

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $77,538 2 payments
Prospective Randomized Masked Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease (SAHARA) $77,295 6 payments
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma $70,983 15 payments
K-321-201 $34,727 10 payments
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $22,440 5 payments
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $18,062 5 payments
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $17,075 8 payments
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma $10,562 1 payment
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma $3,383 1 payment
1698-301-007 Ph3b Study (M21-488) $2,970 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.